mibavademab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ObesityAmenorrhea

177 competitors in Obesity

#DrugCompanyPhaseTrials

1

Maridebart Cafraglutide

Amgen

Phase 3

112

Cagrisema

Novo Nordisk

Phase 3

53

Eloralintide

Eli Lilly

Phase 3

134

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Phase 3

25

PF-08653944

Pfizer

Phase 3

66

mibavademab

Regeneron

Phase 3

17

Ribupatide

KKailera

Phase 3

38

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

19

Actemra

Roche

Preclinical

210

Avapro

Sanofi

Preclinical

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Generalized Lipodystrophy2 trials

A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy (LAGO)

Recruiting·Regeneron·Phase 3·NCT07220785·28 enrolled

A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Metreleptin to Mibavademab, A Leptin Receptor Agonist Antibody

Completed·Regeneron·Phase 3·NCT06548100·9 enrolled

Obesity1 trial

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting·Eli Lilly·Phase 2·NCT06373146·392 enrolled

Amenorrhea1 trial

A Phase 2, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Recruiting·Regeneron·Phase 2·NCT07235917·34 enrolled

Monogenic Obesity1 trial

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

Recruiting·Regeneron·Phase 3·NCT07220772·4 enrolled

Details

Drug Info

Related News